NCT04754425 2026-02-06
Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
M.D. Anderson Cancer Center
Ourotech, Inc.
Canadian Cancer Trials Group
H. Lee Moffitt Cancer Center and Research Institute
Dana-Farber Cancer Institute
University Health Network, Toronto